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Abstract
Background: Testicular germ cell tumors are the most common cancer diagnosed in
young men, and seminomas are the most common type of these cancers. There have
been no exome-wide examinations of genes mutated in seminomas or of overall rates of
nonsilent somatic mutations in these tumors.
Objective: The objective was to analyze somatic mutations in seminomas to determine
which genes are affected and to determine rates of nonsilent mutations.
Design, setting, and participants: Eight seminomas and matched normal samples were
surgically obtained from eight patients.
Intervention: DNA was extracted from tissue samples and exome sequenced on mas-
sively parallel Illumina DNA sequencers. Single-nucleotide polymorphism chip-based
copy number analysis was also performed to assess copy number alterations.
Outcome measurements and statistical analysis: The DNA sequencing read data were
analyzed to detect somatic mutations including single-nucleotide substitutions and
short insertions and deletions. The detected mutations were validated by independent
sequencing and further checked for subclonality.
Results and limitations: The rate of nonsynonymous somatic mutations averaged
0.31 mutations/Mb. We detected nonsilent somatic mutations in 96 genes that were
not previously known to be mutated in seminomas, of which some may be driver
mutations.Many of themutations appear to have been present in subclonal populations.
In addition, two genes, KIT and KRAS, were affected in two tumors each with mutations
that were previously observed in other cancers and are presumably oncogenic.
Conclusions: Our study, the ﬁrst report on exome sequencing of seminomas, detected
somatic mutations in 96 new genes, several of which may be targetable drivers.
Furthermore, our results show that seminoma mutation rates are ﬁve times higher
than previously thought, but are nevertheless low compared to other common cancers.
Similar low rates are seen in other cancers that also have excellent rates of remission
achieved with chemotherapy.
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1. Introduction
Testicular germ cell tumors (TGCTs) are the most common
cancer in young men and occur predominantly in Western
populations. Striking characteristics of TGCTs are their early
stem-cell origins [1] and extreme sensitivity to cisplatin-
based chemotherapy or radiotherapy, which renders them
highly curable [2,3]. However, rates of TGCT incidence have
increased in most populations studied in the last several
decades [4]. This strongly suggests that environmental
factors contribute to TGCTs [5]. Nevertheless, their etiology
is still poorly understood. It has been hypothesized that the
mutation rates of tumor types correlate with resistance to
treatment, and thus that the sensitivity of seminomas to
treatment is indicative of low mutation rates [6]. However,
little is known about the roles of somatic mutations in the
development of TGCTs in general and seminomas in
particular. In this study we investigated previously unde-
scribed genetic events that may drive the development of
seminomas.
Seminomas are typically approximately triploid and
almost all have amplifications involving chromosome arm
12p [7]. Although functional studies have not definitively
identified the driver gene or genes on 12p [8], KRAS is likely
to be one such gene, as it is a well-established oncogene
located in a minimum overlapping amplification region,
and it sometimes undergoes activating point mutations in
TGCTs [9]. Furthermore, cultured seminoma cells with
codon-12 KRAS mutations exhibited suppressed apoptosis
and enhanced survival [10].
The largest study of point mutations in TGCTs to date
examined 518 kinases in 13 tumors. This study found one
mutation (in the STK10 gene) in a total of 17.7Mb examined
across all 13 tumors combined, corresponding to a rate of
0.06mutations/Mb (95% confidence interval [CI] 0.003–0.37)
[11].
Other than KRAS, the only oncogene known to recur-
rently undergo somatic point mutations in seminomas is
KIT, which is often mutated, amplified, and overexpressed
[12]. Somatic activating KIT mutations occur in 16% of
seminomas (95% CI 12–22%) [13]. Indeed, mutations occur
more often in KIT than in KRAS [10,14]. In addition, the
presence of KIT mutations and amplifications in precursor
lesions suggests that KIT is a key contributor to tumor
initiation [15].
In summary, little is known about specific driver genes
mutated in seminomas or the overall rate of somatic point
mutations in these tumors. To investigate these questions,
we undertook exome sequencing and analysis of copy
number alterations in eight seminomas and matched
normal DNA.
2. Materials and methods
2.1. Patient samples
Patient samples and clinical information (Supplementary Table 1) were
obtained from patients who had surgery for testicular cancer at the
Spectrum Health Hospital, Grand Rapids, MI, USA. Informed consent
was obtained from all subjects, and the study was approved by the
Institutional Review Boards of the Van Andel Research Institute, Grand
Rapids, MI, USA (Protocol #011228BT), Spectrum Health, Grand Rapids,
MI, USA (IRB# 2002-087), and the National University of Singapore
(NUS-IRB Reference Code 11-192E).
2.2. Single-nucleotide polymorphism microarrays and ASCAT
analysis
The Supplementary methods provide details regarding the use of ASCAT
(http://heim.iﬁ.uio.no/bioinf/Projects/ASCAT/) to simultaneously esti-
mate the proportion ofmalignant cells present in a tumor and the integer
copy numbers of chromosomes in the tumor genomes. ASCAT estimated
that seven of the eight tumors were approximately triploid, which is
consistent with previous studies of seminoma karyotypes and therefore
lends conﬁdence to the ASCAT analyses.
2.3. Subclonality analysis
We used two approaches to assess whether a somatic mutation was
likely to be subclonal, that is, not present in all the malignant cells of a
tumor. In the ﬁrst approach, we performed a statistical test to check if the
proportions of reads with mutations were signiﬁcantly lower than
expected based on the conservative model that the somatic mutation
was present on only one chromosome (using prop.test in R, Supplemen-
tary Tables 2 and 3). To determine the expected proportion of reads with
the mutation, we used ASCAT estimates of the chromosome copy
number at the mutated site and of the proportion of malignant cells in
the tumor. In the second approach we used the ABSOLUTE software [16]
to determine the probability that each mutation was clonal (Fig. 1,
Supplementary Fig. 1). We considered that a variant was subclonal if this
probability was <0.5.
3. Results
We sequenced the exomes of eight nonmetastatic semi-
nomas to an averagemapped depth of 318 reads in targeted
Patient summary: We examined the DNA sequences of seminomas, the most common
type of testicular germ cell cancer. Our study identiﬁed 96 new genes inwhichmutations
occurred during seminoma development, some of which might contribute to cancer
development or progression. The study also showed that the rates of DNA mutations
during seminoma development are higher than previously thought, but still lower than
for other common solid-organ cancers. Such low rates are also observed among other
cancers that, like seminomas, show excellent rates of disease remission after chemo-
therapy.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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regions; we sequenced the exomes of matched nonmalig-
nant samples to an average mapped depth of 92 reads
(Supplementary Table 4). On average, 98% of targeted bases
were covered by more than ten reads in the tumor samples.
Coverage of receptor tyrosine kinases and genes in the
PI3K/AKT/mTOR and RAS/RAF/MAPK pathwayswas general-
ly very good: the median read depth in tumors for each
group of genes was >240 (Supplementary Fig. 2 and
Supplementary Tables 5–7). After read mapping, we used
three variant callers tomaximize sensitivity (Supplementary
methods) and visually inspected the candidate variants in
Integrative Genomics Viewer (http://www.broadinstitute.
org/igv/). Nonsilent variants that passed visual inspection
were validated by Sanger sequencing or sequencing on an
Ion Torrent Personal Genome Machine (Supplementary
methods and Supplementary Table 8). Overall validation
rates were 83.2% for single-nucleotide substitution (SNS)
mutations and 42.1% for microindels (small insertions or
deletions).
Supplementary Table 2 lists the validated somatic
nonsilent variants found in the eight tumors, together with
their characteristics.
The eight tumors bore a total of 90 somatic nonsilent
SNSs, two double substitutions, eight coding microindels,
and 35 silent mutations. On average, there were 12.5 so-
matic nonsilent mutations per tumor (median 11.5, range
2–27, Table 1 and Supplementary Table 2) and four somatic
silent mutations per tumor (median 3, range 1–13, Table 1
and Supplementary Table 3). The rate of nonsynonymous
mutations in the exome averaged 0.31 mutations/Mb
(median 0.3, range 0.05–0.69). There was a weak associa-
tion between patient age and the number of mutations
(Pearson correlation coefficient 0.71, p = 0.047), although
this was not significant after considering multiple hypoth-
esis testing.
In the tumors we studied, only the oncogenes KIT and
KRAS [10,12,14,17] were affected by nonsilent mutations in
more than one tumor. KRAS harbored the G12V mutation
and was amplified in two tumors. In one of these, KRASwas
present in ten copies, of which we estimate that one bore
the mutation (Supplementary Table 9). In the other tumor,
KRAS was present in six copies, of which we estimate that
two bore the mutation (Supplementary Table 9).
KIT harbored the mutations N822K and L576P in one
tumor each, and eachmutation has been reported previously
in various types of tumor. N822K was reported previously in
seminomas [11,15,17], melanomas, and gastrointestinal
stromal tumors, and L576P was reported in TGCTs, melano-
mas, gastrointestinal stromal tumors, and breast and thymic
carcinomas (http://cancer.sanger.ac.uk/cosmic). In the semi-
noma we studied, the L576P mutation was in a highly
amplified region (more than eight copies) that was also
subject to loss of heterozygosity. We estimate that all eight
copies bore the mutation (Supplementary Table 9). Notably,
this tumor also had the lowest level of 12p amplification
(only 1.44 times the average ploidy).
More than half of the somatic mutations detected were
present in very low proportions of the reads (<15%,
Supplementary Tables 2 and 3). Two independent analyses
indicated that many of these mutations were present in
only a subset of the malignant cells of the tumors. The first
Table 1 – Summary of somatic mutations in each tumor (capture target size 37.81 Mb)
Tumor NSYN
SNVs
Splice-site
SNVs
Micro-indels NSYN
mutations
Nonsilent
mutations
Silent
mutations
Total somatic
mutations
(n) (n) (n) (n) (n/Mb) (n) (n) (n/Mb) (n) (n/Mb)
28 2 0 0 2 0.053 2 2 0.053 4 0.106
31 7 1 0 7 0.185 8 2 0.053 10 0.264
34 20 1 6 26 0.688 27 3 0.079 30 0.793
39 3 0 1 4 0.106 4 1 0.026 5 0.132
40 12 0 1 13 0.344 13 3 0.079 16 0.423
58 20 3 0 20 0.529 23 13 0.344 36 0.952
62 13 0 0 13 0.344 13 5 0.132 18 0.476
73 10 0 0 10 0.264 10 6 0.159 16 0.423
Average 10.88 0.63 1 11.88 0.314 12.5 4.38 0.116 16.88 0.446
Median 11 0 0 11.5 0.304 11.5 3 0.079 16 0.423
NSYN = nonsynonymous; SNVs = single-nucleotide variations.
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Fig. 1 – Clonal composition of somatic mutations in each sample. Each
bar indicates the number of clonal and subclonal mutations for one
tumor as inferred using ABSOLUTE.
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analysis compared the actual read counts of each mutation
to the minimum that would be expected based on (1) the
proportion of malignant cells in the tumor sample and (2)
the chromosomal copy number at the mutation site, as
described in Section 2. The second analysis used the
ABSOLUTE software [16], which has also been used in
several recent studies of subclonality [18,19]. ABSOLUTE
detects subclonal heterogeneity based on the proportions of
reads bearing somatic mutations and a sophisticated model
that simultaneously estimates the proportion of malignant
cells in the sample and chromosomal copy numbers across
the genome. The model also takes into consideration
sampling variation with respect to the true proportion of
mutation-bearing reads. Given the more complete model of
ABSOLUTE, we expected it to be more sensitive. Indeed,
ABSOLUTE identified 72 mutations as subclonal, while
the first method identified 46 (Fig. 1, Supplementary
Tables 2 and 3, Supplementary Fig. 1). However, out of
46 somatic mutations estimated to be subclonal by the first
method,40werealsoestimated tobesubclonalbyABSOLUTE
(Supplementary Tables 2 and 3). Thus, bothmethods support
the conclusion that there were a substantial proportion of
subclonal somatic mutations.
Besides KIT and KRAS, our genomic analysis revealed
several genes with plausible driver roles in this tumor type.
For example, the CHD1 gene, which encodes a chromodo-
main helicase DNA-binding protein, was associated with
both frameshift mutations and genomic deletions in our
cohort (Supplementary Table 2), consistent with a tumor
suppressor role. Interestingly, tumor-suppressive roles for
CHD1 have also been reported in prostate cancer, another
male-organ–specific malignancy [20,21]. Another gene
exhibiting a dual pattern of mutation and genomic loss
was MCC, which has been implicated in tumor-suppressive
roles in colorectal cancer [22]. Experimental work has
shown that MCC can inhibit several cancer phenotypes,
including cell cycle progression and oncogenic Wnt
signaling [23,24]. A third gene exhibiting mutation/
genomic loss was SMARCA5, a member of the SWI/SNF
chromatin remodeling complex. Mutations in SWI/SNF
complex members have been repeatedly observed in
multiple tumor types [25,26], and such mutations may
influence somatic patterns in gene expression and chromo-
somal instability in tumors. Supplementary Table 10 pro-
vides a more extensive list of nonsilent somatic mutations
with potential driver functions. The mutations in some of
these potential drivers appear to be subclonal; this has also
been observed in other tumor types [18].
Several of the mutated potential driver genes may be
therapeutically targetable. The products of two mutated
genes, CSNK2A and PIK3R2, have functions in important
enzymatic complexes (casein kinase 2 and class I phosphoi-
nositol-3-kinases, respectively) that have attracted substan-
tial interest as potential drug targets in cancer
(Supplementary Table 10). In addition, CDH17, which was
clonally mutated in one seminoma, has been implicated in
gastric cancer progression [27] andmay represent apotential
therapeutic target, as CDH17 knockdown in mice inhibited
tumor growth [28]. Another potential target is SETDB1, a
histone methyltransferase that may act as an oncogene in
multiple tumor types [29,30] and that is downregulated by
the histone methylation inhibitor DZNep [31].
Because seminomas arise from germ cells, threemutated
genes are of interest because, to the best of our knowledge,
their functions are germ-cell–specific. GTF2A1L encodes a
component of a germ-cell–specific general transcription
factor [32]. DZIP3 encodes an E3 ubiquitin ligase with an
RNA-binding domain and interacts with the DAZ protein,
which is essential for normal spermatogenesis [33]. Finally,
SPATS1 (also known as SRSP1) is a serine-rich gene of largely
unknown function with a rat homolog that is expressed
during spermatogenesis [34].
Single-nucleotide polymorphism microarray data
showed that the seminomas studied were typical with
respect to copy-number alterations (Fig. 2, Supplementary
Fig. 3). Seven of the eight tumors studied were approxi-
mately triploid, and all had amplifications involving 12p. As
expected from previous studies, the region containing KRAS
[(Fig._2)TD$FIG]
Fig. 2 – Summary of copy number alterations in the eight seminomas. The heat map shows the copy number values across the chromosomes for each
tumor. White represents regions with copy number equal to the average ploidy of the tumor; red represents copy-number gain and blue represents
copy-number loss.
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was included in all 12p amplifications, and KRASwas highly
amplified (copy number >2.5 times the average ploidy) in
five out of the eight tumors. As mentioned above, two of the
tumors with KRAS amplifications also had somatic muta-
tions in this gene (Supplementary Table 2). Other large
chromosomal aberrations found in two or more seminomas
included copy-number gains involving 2q, 7, 8, 12q, 21q,
22q, and X (Fig. 2, Supplementary Table 11, Supplementary
Fig. 3) and copy-number losses involving 3p, 4, 5, 9, 11q,
13q, 16q, and 18 (Fig. 2, Supplementary Table 12, Supple-
mentary Fig. 3). Copy-number alterations involving these
regions were detected previously in other cancer types
(Supplementary Table 13). Regions of copy-number gain
harbored eight nonsilent mutations (including those in KIT
and KRAS), and regions of copy-number loss harbored ten
nonsilent mutations (Supplementary Table 2). In addition,
five mutations were found in regions with loss of
heterozygosity, including one in KIT in a highly amplified
region, as discussed above (Supplementary Tables 2 and 9).
4. Discussion
This study enlarges the list of genes known to bemutated in
seminomas. In total, 98 distinct genes were affected by
nonsilent mutations, and only two of these genes, KIT and
KRAS, were previously implicated in TGCTs [10,12,
14,17]. Thus, we detected nonsilent somatic mutations in
96 genes that were not previously known to be mutated in
seminomas. As detailed above, the known functions of
affected genes suggest that some of these mutations could
be drivers.
The exome sequencing reported here also provides the
first comprehensive estimate of the somatic mutation rates
in seminomas. While higher than previous estimates based
on very limited data [11], the mutation rates in seminomas
are nevertheless much lower than the rates observed in
many other cancers (Fig. 3) [35].
The low numbers of mutations in seminomas might be
related to their sensitivity to therapy [6]. Most advanced-
stage cancers are incurable, even with aggressive chemo-
therapy; although chemotherapy can lead to initial disease
regression, the cancer invariably becomes resistant to drug
treatment, and patients ultimately succumb to the disease.
Seminomas are unique among solid-organ cancers in that
even patients with widely metastatic or advanced-stage
tumors usually achieve a complete clinical response and
long-term remission after several cycles of combination
chemotherapy [2,3]. Several other cancers with low
mutation rates share this characteristic, even in ad-
vanced-stage disease. These include pediatric acute mye-
loid leukemia, pediatric medulloblastoma, and pediatric
acute lymphoblastic leukemia (Fig. 3) [35–38].
If the sensitivity of seminomas to therapy is indeed
related to their low numbers of somatic mutations, this
connection might be explained by the theory that with a
low number of somatic mutations, seminomas have little
chance of harboring pre-existing clones with drug resis-
tance mutations. By contrast, the low number of mutations
may simply reflect the relatively young ages of the patients,
especially considering that the cells of origin are probably
quiescent during childhood. The low numbers of mutations
might also be a consequence of the stem-cell origins of
seminomas, which might require fewer aberrations to
develop an oncogenic or even metastatic phenotype.
Although not investigated here, it is possible that relatively
few genetic changes are required for metastasis of
[(Fig._3)TD$FIG]
Fig. 3 – Comparison of the number of nonsynonymous mutations per
tumor in seminomas and blood, pediatric, and adult solid tumors.
Lower and upper horizontal bars indicate the first and third quartiles;
middle bars indicate the median. The numbers of mutations in
nonseminoma cancers are from Supplementary Table S1C of reference
[35]. NSCLC = non–small-cell lung cancer; EAC = esophageal
adenocarcinoma; MSS = microsatellite stable;ESCC = esophageal
squamous-cell carcinoma; SCLC = small-cell lung cancer; MSI =
microsatellite instability.
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seminomas, a possibility supported by the similarity of
transcript profiles in primary and metastatic seminomas
[39]. This may explain the vulnerability of even metastatic
seminomas to therapy.
5. Conclusions
Our results, the first reported for exome sequencing of
seminomas, identified 96 new genes harboring somatic
mutations in seminomas; the mutations and known
functions of some of these genes suggest that they could
be drivers, of which several are potential drug targets. This
study also provides the first comprehensive estimate of
somatic mutation rates in seminomas. These rates are five
times higher than previously estimated from very limited
data, but are nevertheless low than those for other common
solid-organ cancers. The low rates seen in seminomas are
also observed among other cancers that share excellent
rates of disease remission achieved with chemotherapy.
Microarray and read data are deposited at the European
Genome-phenome Archive (http://www.ebi.ac.uk/ega, ac-
cession number EGAS00001000943).
Author contributions: Steven G. Rozen had full access to all the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Cutcutache, Rozen.
Acquisition of data: Ramgopal, Zhang, Ramnarayanan, Gan, Lee, Tay, Ooi,
Ong, Bolthouse, Lane, Anema, Kahnoski, P. Tan, Teh.
Analysis and interpretation of data: Cutcutache, Rozen.
Drafting of themanuscript: Cutcutache, Suzuki, I.B. Tan, P. Tan, Teh, Rozen.
Critical revision of the manuscript for important intellectual content:
Cutcutache, P. Tan, Teh, Rozen.
Statistical analysis: Cutcutache, Rozen.
Obtaining funding: P. Tan, Teh, Rozen.
Administrative, technical, or material support: None.
Supervision: Rozen, Teh, P. Tan.
Other: None.
Financial disclosures: Steven G. Rozen certiﬁes that all conﬂicts of
interest, including speciﬁc ﬁnancial interests and relationships and
afﬁliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/afﬁliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents ﬁled, received, or pending), are the following: None.
Funding/Support and role of the sponsor: This study was supported by
the Duke-NUS Signature Research Programs, funded by the Singapore
Ministry of Health. The sponsor played no role in the study.
Acknowledgments: We thank Sabrina Noyes for coordinating tissue
samples and associated clinical data; Amreena Shamit for assistance in
surveying the literature on the genes affected by nonsilent mutations;
Andre´ Vettore for assistance in using the Partek software; and John
McPherson, Alvin Ng, Yew Chung Tang, Andre´ Vettore, and Willie Yu for
comments on the manuscript.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
eururo.2014.12.040.
References
[1] Rajpert-De Meyts E. Developmental model for the pathogenesis of
testicular carcinoma in situ: genetic and environmental aspects.
Hum Reprod Update 2006;12:303–23.
[2] Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci
U S A 2002;99:4592–5.
[3] Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a
phase III study of three versus four cycles of bleomycin, etoposide,
and cisplatin in favorable-prognosis germ-cell tumors: the Indian
University experience. J Clin Oncol 1998;16:702–6.
[4] Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International
patterns and trends in testis cancer incidence. Int J Cancer 2005;
115:822–7.
[5] Richiardi L, Pettersson A, Akre O. Genetic and environmental risk
factors for testicular cancer. Int J Androl 2007;30:230–40.
[6] Yaes RJ. Tumor heterogeneity, tumor size, and radioresistance. Int J
Radiat Oncol Biol Phys 1989;17:993–1005.
[7] Oosterhuis JW, Gillis AJ, van Putten WJ, de Jong B, Looijenga LH.
Interphase cytogenetics of carcinoma in situ of the testis. Numeric
analysis of the chromosomes 1, 12 and 15. Eur Urol 1993;23:16–21.
[8] Looijenga LH, Zafarana G, Grygalewicz B, et al. Role of gain of 12p in
germ cell tumour development. APMIS 2003;111:161–71.
[9] McIntyre A, Summersgill B, Spendlove HE, Huddart R, Houlston R,
Shipley J. Activating mutations and/or expression levels of tyrosine
kinase receptors GRB7, RAS, and BRAF in testicular germ cell
tumors. Neoplasia 2005;7:1047–52.
[10] Olie RA, Looijenga LH, Boerrigter L, et al. N- and KRAS mutations in
primary testicular germ cell tumors: incidence and possible bio-
logical implications. Genes Chromosomes Cancer 1995;12:110–6.
[11] Bignell G, Smith R, Hunter C, et al. Sequence analysis of the protein
kinase gene family in human testicular germ-cell tumors of ado-
lescents and adults. Genes Chromosomes Cancer 2006;45:42–6.
[12] Goddard NC, McIntyre A, Summersgill B, Gilbert D, Kitazawa S,
Shipley J. KIT and RAS signalling pathways in testicular germ cell
tumours: new data and a review of the literature. Int J Androl
2007;30:337–48.
[13] Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur
predominantly in seminoma germ cell tumors and are not predic-
tive of bilateral disease: report of 220 tumors and review of
literature. Genes Chromosomes Cancer 2008;47:34–42.
[14] Sommerer F, Hengge UR,Markwarth A, et al. Mutations of BRAF and
RAS are rare events in germ cell tumours. Int J Cancer 2005;113:
329–35.
[15] Biermann K, Goke F, Nettersheim D, et al. c-KIT is frequently
mutated in bilateral germ cell tumours and down-regulated during
progression from intratubular germ cell neoplasia to seminoma.
J Pathol 2007;213:311–8.
[16] Carter SL, Cibulskis K, Helman E, et al. Absolute quantiﬁcation of
somatic DNA alterations in human cancer. Nat Biotechnol 2012;30:
413–21.
[17] Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common
in testicular seminomas. Am J Pathol 2004;164:305–13.
[18] Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of
subclonal mutations in chronic lymphocytic leukemia. Cell 2013;
152:714–26.
[19] Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heteroge-
neity in multiple myeloma: implications for targeted therapy.
Cancer Cell 2014;25:91–101.
[20] Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR.
Recurrent deletion of CHD1 in prostate cancer with relevance to
cell invasiveness. Oncogene 2012;31:4164–70.
[21] Burkhardt L, Fuchs S, Krohn A, et al. CHD1 is a 5q21 tumor
suppressor required for ERG rearrangement in prostate cancer.
Cancer Res 2013;73:2795–805.
E U RO P E AN URO LOG Y 6 8 ( 2 0 1 5 ) 7 7 – 8 382
[22] Kinzler KW, Nilbert MC, Su LK, et al. Identiﬁcation of FAP locus
genes from chromosome 5q21. Science 1991;253:661–5.
[23] Matsumine A, Senda T, Baeg GH, et al. MCC, a cytoplasmic protein
that blocks cell cycle progression from the G0/G1 to S phase. J Biol
Chem 1996;271:10341–6.
[24] Pangon L, Mladenova D, Watkins L, et al. MCC inhibits beta-catenin
transcriptional activity by sequestering DBC1 in the cytoplasm. Int J
Cancer 2015;136:55–64.
[25] Gigek CO, Lisboa LC, Leal MF, et al. SMARCA5 methylation and
expression in gastric cancer. Cancer Invest 2011;29:162–6.
[26] Helming KC, Wang X, Roberts CW. Vulnerabilities of mutant SWI/
SNF complexes in cancer. Cancer Cell 2014;26:309–17.
[27] Zhang J, Liu QS, Dong WG. Blockade of proliferation and migration
of gastric cancer via targeting CDH17 with an artiﬁcial microRNA.
Med Oncol 2011;28:494–501.
[28] Qiu HB, Zhang LY, Ren C, et al. Targeting CDH17 suppresses tumor
progression in gastric cancer by downregulating Wnt/beta-catenin
signaling. PLoS One 2013;8:e56959.
[29] Sun QY, Ding LW, Xiao JF, et al. SETDB1 accelerates tumorigenesis
by regulating WNT signaling pathway. J Pathol. In press. http://dx.
doi.org/10.1002/path.4482
[30] Ceol CJ, Houvras Y, Jane-Valbuena J, et al. The histone methyltrans-
ferase SETDB1 is recurrently ampliﬁed in melanoma and acceler-
ates its onset. Nature 2011;471:513–7.
[31] Lee JK, Kim KC. DZNep, inhibitor of S-adenosylhomocysteine hy-
drolase, down-regulates expression of SETDB1 H3K9me3 HMTase
in human lung cancer cells. Biochem Biophys Res Commun
2013;438:647–52.
[32] Upadhyaya AB, Lee SH, DeJong J. Identiﬁcation of a general tran-
scription factor TFIIAalpha/beta homolog selectively expressed in
testis. J Biol Chem 1999;274:18040–8.
[33] Shigunov P, Sotelo-Silveira J, Stimamiglio MA, et al. Ribonomic
analysis of human DZIP1 reveals its involvement in ribonucleopro-
tein complexes and stress granules. BMC Mol Biol 2014;15:12.
[34] Geisinger A, Dos Santos A, Benavente R, Wettstein R. Identiﬁcation
and characterization of SRSP1, a rat gene differentially expressed
during spermatogenesis and coding for a serine stretch-containing
protein. Cytogenet Genome Res 2002;98:249–54.
[35] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA,
Kinzler KW. Cancer genome landscapes. Science 2013;339:1546–58.
[36] Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards
high-quality cure of all patients. Haematologica 2007;92:1519–32.
[37] Gerber N, MynarekM, von Hoff K, Friedrich C, Resch A, Rutkowski S.
Recent developments and current concepts in medulloblastoma.
Cancer Treat Rev 2014;40:356–65.
[38] Salzer W, Devidas M, Carroll W, et al. Long-term results of the
pediatric oncology group studies for childhood acute lymphoblastic
leukemia 1984–2001: a report from the children’s oncology group.
Leukemia 2009;24:355–70.
[39] Ruf CG, Port M, Schmelz HU, et al. Clinically apparent and occult
metastasized seminoma: almost indistinguishable on the tran-
scriptional level. PLoS One 2014;9:e95009.
E U RO P E AN URO L OGY 6 8 ( 2 0 1 5 ) 7 7 – 8 3 83
